Cinzia Orlandini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cinzia Orlandini has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Chioni
Department of Medical Oncology, Pisa University Hospital, Pisa, Italy
1 shared publication - Aldo Sainato
Radiation Oncology, Pisa University Hospital, 56126 Pisa, Italy
1 shared publication - Alessandra Galardi
Department of Radiotherapy, Florence University, Italy
1 shared publication - Antonino De Paoli
Department of Radiation Oncology, Centro di Riferimento Oncologico, Aviano, Italy
1 shared publication - Bruno Manfredi
U.O. Radioterapia, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
1 shared publication - Claudia Cianci
Department of Medical Oncology, Pisa University Hospital, Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 27 September 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 1-9
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Background: The selection of patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in Castration-Resistant Prostate Cancer (CRPC) patients. Functional polymorphisms within thecytochrome P450 1B1(CYP1B1) gene have been associated with alterations in enzymatic expression and activity and may change sensitivity to the widely used docetaxel regimen.Methods: CYP1B1genotyping was performed on blood samples of 60 CRPC patients treated with docetaxel, using TaqMan probes-based assays. Association betweenCYP1B1-142C>G (leading to the 48ArgGly transition), 4326C>G (432LeuVal), and 4390A>G (453AsnSer) polymorphisms and treatment response, progression-free-survival (PFS) and overall-survival (OS) was estimated using Pearson χ2test, Kaplan-Meier curves and Log-rank test.Results: Patients carrying theCYP1B1-432ValVal genotype experienced a significantly lower response-rate (P = 0.014), shorter progression-free-survival (P = 0.032) and overall-survival (P < 0.001). Multivariate analyses and correction for multiple comparisons confirmed its prognostic significance for OS. No significant associations were found among other polymorphisms and both response and clinical outcome.Conclusions: CYP1B1-4326C>G (432LeuVal) polymorphism emerged as possible predictive marker of response and clinical outcome to docetaxel in CRPC patients and may represent a potential new tool for treatment optimization. Larger prospective trials are warranted to validate these findings, which might be applied to the future practice of CRPC treatment.
- 27 September 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 1-9
Open AccessCytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Background: The selection of patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in Castration-Resistant Prostate Cancer (CRPC) patients. Functional polymorphisms within thecytochrome P450 1B1(CYP1B1) gene have been associated with alterations in enzymatic expression and activity and may change sensitivity to the widely used docetaxel regimen.Methods: CYP1B1genotyping was performed on blood samples of 60 CRPC patients treated with docetaxel, using TaqMan probes-based assays. Association betweenCYP1B1-142C>G (leading to the 48ArgGly transition), 4326C>G (432LeuVal), and 4390A>G (453AsnSer) polymorphisms and treatment response, progression-free-survival (PFS) and overall-survival (OS) was estimated using Pearson χ2test, Kaplan-Meier curves and Log-rank test.Results: Patients carrying theCYP1B1-432ValVal genotype experienced a significantly lower response-rate (P = 0.014), shorter progression-free-survival (P = 0.032) and overall-survival (P < 0.001). Multivariate analyses and correction for multiple comparisons confirmed its prognostic significance for OS. No significant associations were found among other polymorphisms and both response and clinical outcome.Conclusions: CYP1B1-4326C>G (432LeuVal) polymorphism emerged as possible predictive marker of response and clinical outcome to docetaxel in CRPC patients and may represent a potential new tool for treatment optimization. Larger prospective trials are warranted to validate these findings, which might be applied to the future practice of CRPC treatment.